Key points
- In the first CT/MRI study, midfacial volume fell about 7% for every 10 kg lost, mostly in superficial fat [3].
- Facial and skin changes tracked the magnitude of weight loss. Reviews find no proven drug-specific facial effect [4][5].
- Hair loss was more common than with placebo (RR 3.25), with an event rate of 3.9%, mainly telogen effluvium [9][10].
- 82% of ASPS surgeons received GLP-1-related consultation requests in 2025, and facial fat grafting grew 39% [7].
- Fillers, biostimulators and fat grafting show results in case series and models. There are still no randomized trials in this population [11][12][13].
US status (October 2026): Semaglutide is approved as Ozempic, Rybelsus and Wegovy, and tirzepatide as Mounjaro and Zepbound. See the semaglutide and tirzepatide status pages.
The “GLP-1 face” is the face of rapid, substantial weight loss. The data so far tie it to kilograms lost, with no proven drug-specific effect. The treatments your patients will ask for rest on case series, surveys and one computer model.
The weight loss is the benefit
In STEP 1, semaglutide 2.4 mg weekly was associated with a mean 14.9% weight reduction at 68 weeks vs 2.4% with placebo [1]. In SURMOUNT-1, tirzepatide 15 mg reached a 20.9% reduction at 72 weeks vs 3.1% with placebo, and 57% of those on that dose lost 20% or more of their body weight [2].
Weight loss of that size, once seen only after bariatric surgery, also changes the face. The media called it “Ozempic face.” A systematic review of 23 plastic surgery articles found that online searches for the term were linked to rising searches for “face filler” and “plastic surgeons” [6]. For your aesthetic practice, it is a manageable consequence and a demand that is already arriving.
Imaging shows 7% less midfacial volume per 10 kg
The first quantitative data come from a retrospective Vanderbilt study of 20 patients who had head and neck CT or MRI before and after starting a GLP-1 agonist [3]. With a mean weight loss of 11.0 kg over about 321 days, total midfacial volume fell by a median 9.0%: 11.0% in superficial fat and 7.0% in deep fat [3]. Weight loss correlated with superficial volume loss, with no such link for deep fat. Regression estimated 7% less midfacial volume for every 10 kg lost [3].
- 7%: less midfacial volume for every 10 kg lost [3]
- 82%: of ASPS surgeons received GLP-1 consultation requests in 2025 [7]
- 39%: growth in US facial fat grafting in 2025 [7]
The changes track weight lost, with no proven drug effect
A survey of 1,226 patients in a weight-management program showed a clear link to magnitude. Among those who lost more than 20% of body weight, 72% reported skin sagging and 50% decreased facial volume. Among those who lost less than 10%, the figures were 15% and 13% [4]. The authors note that greater weight loss occurred more often with GLP-1s than with other treatments [4].
A 2026 review put it this way: “The facial volume loss and skin laxity popularly described as ‘Ozempic face’ more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect” [5].
We found no imaging studies comparing the face after GLP-1s with the face after equivalent loss from diet or surgery. The prudent reading is to treat the “GLP-1 face” as the face of rapid, substantial weight loss [5].
Hair loss is real and mostly telogen effluvium
In the same survey, 52% of those who lost more than 20% of body weight reported hair loss, vs 17% of those who lost less than 10% [4]. A meta-analysis of nine interventional studies (4,114 GLP-1 users) found more hair loss than with placebo (RR 3.25; 95% CI 1.44 to 7.36), with an event rate of 3.9% [9]. Another meta-analysis, pooling cohort and pharmacovigilance data, associated these drugs with a 40% increase in non-scarring alopecia (OR 1.40), driven by telogen effluvium and androgenetic alopecia. Alopecia areata was not associated [10]. Its authors attribute this mainly to weight-loss-related micronutrient deficiency and recommend counseling and nutritional optimization over premature drug discontinuation [10].
Some skin news is good. Among surveyed GLP-1 users, improvement was reported by 87% of those with hidradenitis suppurativa (13 of 15), 47% of those with psoriasis and 41% of those with acne [4]. These are patient-reported data without a control group [4]. For bone, micronutrients and lean mass, see GLP-1s: muscle, rebound, eyes and pancreas.
Patients are already asking: the ASPS numbers
The 2025 statistics report of the American Society of Plastic Surgeons (ASPS) devoted a chapter to GLP-1s. 82% of its surgeons received consultation requests related to these drugs [7]. For the face, the most cited were facelift (71%), neck lift (64%), eyelid surgery (37%) and brow lift (19%). For the body, tummy tuck (88%) and breast surgery (87%) [7]. Facial fat grafting was the fastest-growing cosmetic surgical procedure, up 39% to 34,117 cases [7]. For facial rejuvenation, surgeons cited hyaluronic acid fillers first (69%), then autologous fat grafting (49%) [7].
The report itself cautions that “consultations and procedures are not synonymous”: tummy tuck was the most frequent consultation, yet its volume grew only 2% [7]. In a survey of 406 aesthetic professionals, the number of patients on GLP-1s rose by a mean 137% from 2023 to 2024. Midface volume loss and face and neck laxity were the changes most cited [8].
The treatments studied, and how strong the evidence is
| Treatment | Best evidence | Limits |
|---|---|---|
| Hyaluronic acid plus poly-L-lactic acid (PLLA) | Case series of 15 women [11] | Retrospective, no control group, industry ties |
| Calcium hydroxylapatite (CaHA) for prevention | Computer model with 12,000 digital twins [12] | Model predictions, no patients |
| Autologous fat grafting | Fastest-growing technique [7] | No study measured graft outcomes on incretins [13] |
- HA and PLLA. In a multicenter Latin American series of 15 women aged 30 to 50, with 17.9% weight loss, the combination was associated with improvement of the facial laxity scale from 4.5 to 2.6 and of the wrinkle scale from 3.1 to 1.9 at 85 to 100 days. 87% were satisfied, and only transient bruising and edema occurred [11]. Several authors disclose ties to the manufacturer [11]. In the professional survey, hyaluronic acid was considered the best facial treatment for an average 47% of patients [8].
- CaHA and prevention. A “virtual” trial predicted that all preventive injectables reduced sagging. CaHA reduced it most (by 2.74 mm), and hyaluronic acid had an early effect that attenuated (1.11 mm) [12]. The authors stress these are model predictions with no clinical evidence behind them [12].
- Fat grafting. A scoping review found no clinical or preclinical study that directly measured graft outcomes in patients on incretins. The concerns are mechanistic and its recommendations are hypotheses [13].
Fasting and sedation management before any procedure is covered in GLP-1s, aspiration risk and fasting.
Body contouring depends on weight stability
In a matched TriNetX analysis, GLP-1 users who had surgery chose breast procedures more often than post-bariatric patients (56.9% vs 21.7%), while the latter more often had abdominal procedures (84.8% vs 42.1%) [14]. GLP-1 users had less intraoperative hemorrhage (0.07% vs 0.74%) and similar rates of infection, dehiscence and thromboembolism [14]. In a cohort of 552 patients, greater and faster weight loss predicted more seromas and complications, especially with combined bariatric surgery and GLP-1s [15]. A recent review concludes that GLP-1 use is neither an absolute advantage nor an automatic contraindication. Weight stability and nutritional status are among the factors that count [5].
The evidence ends at case series
Almost everything published consists of case series, surveys, narrative reviews and expert opinion [5][6]. The only imaging study has 20 patients and is retrospective [3]. The filler series has 15 patients and industry support [11], and the biostimulator trial is a simulation [12]. Systematic reviews acknowledge biases in the available literature [6]. Prospective studies comparing techniques and timing are lacking [5].
What this means for you
The face loses mainly superficial fat, in proportion to the kilograms lost [3][4]. Patients are already asking for help [7][8]. Plan treatment around weight stability, check nutrition when hair loss appears, and tell patients plainly which treatments are proven and which are not [5]. If you run both a weight-management program and an injectables practice, build the referral between them on these numbers.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185. Link
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024. Link
- Sharma RK, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngol Head Neck Surg. 2025;173(2):360-366. PMID 40407186. Link
- Rao S, et al. Skin impacts and tradeoffs of GLP-1 therapy: improved patient-reported outcomes of inflammatory skin disease in the era of “Ozempic face”. Dermatol Ther (Heidelb). 2026;16(9):4749-4760. PMID 42579223. Link
- Ersan M, Özturhan O. Effects of GLP-1 receptor agonists on aesthetic surgery practice: a contemporary review. Turk J Surg. 2026 (online ahead of print). PMID 42830623. Link
- Daneshgaran G, et al. “Ozempic face” in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthet Surg J Open Forum. 2025;7:ojaf056. PMID 40626110. Link
- American Society of Plastic Surgeons. 2025 Plastic Surgery Statistics Report (The GLP-1 Effect: From Body to Face). 2026. Link
- Fabi S, et al. Aesthetic concerns and nonsurgical treatment trends in patients with GLP-1 agonist-associated weight loss. Dermatol Surg. 2026;52(6S):S23-S28. PMID 42210883. Link
- Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333. PMID 42155605. Link
- Viquez Burboa GU, et al. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disord. 2026 (online ahead of print). PMID 42621629. Link
- Avelar LET, et al. Aesthetic use of poly-L-lactic acid and hyaluronic acid fillers in medication-driven weight loss due to GLP-1 receptor agonists: real-world case series from Latin America. Clin Cosmet Investig Dermatol. 2026;19:620566. PMID 42328491. Link
- Rahman E, et al. Computational trial of prophylactic biostimulator interventions to mitigate facial sagging associated with GLP-1 receptor agonist induced weight loss. Aesthetic Plast Surg. 2026;50(18):7703-7731. PMID 42414642. Link
- Chalhoub X, Yang Ng Z. Do GLP-1 receptor agonists sabotage fat grafts? A scoping review of GLP-1 receptor agonist effects on adipocyte biology and implications for autologous fat transfer. Aesthet Surg J. 2026 (online ahead of print). PMID 42219269. Link
- Smith JE, et al. Outcomes of body contouring surgery after bariatric surgery vs. GLP-1 receptor agonist-induced weight loss: a propensity score matched analysis. Aesthetic Plast Surg. 2026;50(11):4142-4150. PMID 41991800. Link
- Liang J, et al. Massive weight loss with bariatric surgery and GLP-1RA therapy predicts postoperative complications following abdominal body contouring. Plast Reconstr Surg. 2026 (online ahead of print). PMID 42054101. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.